clinical trial · NCT00649168
Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg
HealthyBROMOCRIPTINE MESYLATE CAPSULES, USP 5 mgParlodel® (bromocriptine mesylate) capsules, USP 5 mg
brief summary
The objective of this study was to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg bromocriptine mesylate capsules, following the administration of a 10 mg dose, under fed conditions.
started
Apr 1, 2007
primary completion
Jun 1, 2007
completion
Jun 1, 2007
last updated
Apr 24, 2024
official title
Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg Bromocriptine Mesylate Capsules Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol